Full-spectrum cannabis oil for seizures in tuberous sclerosis
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a full-spectrum cannabis extract to see if it reduces seizures in people with tuberous sclerosis complex (TSC) whose seizures have not been controlled by other treatments. If it works, it could offer a new option for managing hard-to-treat epilepsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 65 years old
- You have tuberous sclerosis complex (TSC) confirmed by a doctor or genetic test
- You have had at least 4 observable seizures in the 4 weeks before starting the trial
- Your seizure medicines or any special diet have been stable for at least 4 weeks before starting
- You are currently taking 3 or fewer seizure medicines (clobazam doesn't count)
- You or your caregiver is willing to keep a daily seizure diary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called SVG103 (Paxalisib) in adults with brain conditions that cause hard-to-control seizures: Focal Cortical Dysplasia Type II, Tuberous Sclerosis Complex, or Hemimegalencephaly. The goal is to see if SVG103 is safe and helps reduce seizures.
This study tests an investigational drug called AV078 for people with tuberous sclerosis complex (TSC) whose seizures are not controlled by at least two current medications. The goal is to see if AV078 can reduce seizure frequency safely, and participants continue their usual seizure medications during the trial.
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
This study tests whether a cannabis-based medicine can reduce seizures in people with epilepsy that hasn't improved with other treatments. It may offer a new option for those who continue to have seizures.
This trial provides access to cannabidiol (CBD), a marijuana-derived compound, for children with severe epilepsy that hasn't improved with standard medications. The goal is to see if CBD can help reduce seizures in this difficult-to-treat group.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
Hear when a new Tuberous Sclerosis Complex (TSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.